Patent Landscape and IP Strategy for Biotech Diligence
Map biotech patent families, assignees, citations, jurisdictions, claims, and whitespace using EPO, Google Patents data, web extraction, and structured IP workflows.
Decision questions
What this solution is built to answer.
Who controls the relevant patent families and jurisdictions?
Where are the material claim, citation, assignee or clearance-review signals?
What filings affect competitive timing or market entry?
Which patent clusters suggest whitespace or crowding?
Science and method
What can change the model or gate.
EPO and Google Patents search paths.
Assignee and inventor portfolio analysis.
Citation mapping and jurisdiction-level evidence.
Patent full-text extraction and fallback web acquisition.
Patent-cliff visuals for competitive deep dives.
Method and decision gates
How the case is computed and reviewed.
| Workflow | Role | Artifacts |
|---|---|---|
| patent-landscape-analysis | IP landscape and whitespace analysis | Patent findings, assignee tables, citation maps, jurisdiction notes |
| competitive-landscape-deepdive | Patent timing inside competitive strategy | Patent cliff, TPP radar, competitive landscape report |
Evidence inputs
Supporting evidence, rights and decision inputs.
Decision record
What remains available for review.
Deliverables
Patent landscape report with assignees, families, citations, and jurisdictions.
Patent-cliff timing visual.
IP risk and whitespace notes for diligence.
Structured input for competitive or BD analysis.
Proof points
The patent specialist has both EPO and Google Patents data paths.
Patent evidence can run as an independent lane in competitive deep dives.
Firecrawl remains available for pages that require heavier extraction.
Limits and review conditions
What this result does not establish.
Patent Studio prepares evidence for business and counsel review. It does not provide a legal opinion, validity finding or clearance conclusion.
FAQ
Common evaluation questions.
Is this a legal opinion?
ARiDA can structure patent evidence and diligence material. Legal opinions, validity findings and clearance conclusions require qualified counsel.
Can patent findings connect to valuation?
Yes. Patent timing, exclusivity, and competitive pressure can feed loss-of-exclusivity assumptions, scenarios, and portfolio risk narratives.
Related solutions
Competitive Intelligence
Build competitive landscapes, TPP comparisons, patent-cliff views, market-share scenarios, and response plans from live web, trial, patent, literature, and database evidence.
Biotech Valuation
Connect scientific evidence and uncertainty to PoS, rNPV, option value and the asset or portfolio decision under review.
Indication Expansion
Scan, assess, and sequence indication opportunities with scientific rationale, clinical feasibility, competitive density, IP context, market structure, and valuation logic.
Related reading
Run a competitive landscape around a decision, not a company list
A useful landscape explains which competitor changes the target profile, timing or investment case.
The missing layer between scientific systems and business models
Biopharma teams still move critical assumptions by hand between evidence tools and financial models.
Auditability is a chain of records, not a citation count
A reviewer needs to trace the question, source, transformation, assumption, result and release state.